Different Disease Pathways to Idiopathic Parkinson’s Disease: Three Genetically-Defined Subgroups with Different Treatment Responses in Phase III Disease-Modifying Trials and Distinct Clinical Trajectories

Antony is a cell & molecular biologist and geneticist with strong research interests into the causative mechanism(s) of Parkinson’s Disease, and therapeutic approaches to successfully treat PD patients, especially with respect to slowing disease progression in idiopathic patients.
Recently in his role as the Research Director of the Australian Parkinson’s Mission, Antony and his collaborators have made substantial progress in identifying three genetically-defined subgroups of idiopathic patients whose analysis supports three differing disease mechanisms.